Effect of treatment with cyproterone acetate on uterine bleeding at the beginning of GnRH analogue therapy in girls with idiopathic central precocious puberty

Hormone Research in Paediatrics

Volumn 73, Issue 5, 2010, Pages 386-389

  Seminara, S ^a   Nanni, L ^a   Generoso, M ^a   Mirri, S ^a   Leonardi, V ^a   Slabadzianiuk, T ^a   Vetrano, M L ^a   Buongiorno, A ^a   Losi, S ^a   Galluzzi, F ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Cyproterone acetate; Flare up effect; GnRH analogue; Precocious puberty, females

Indexed keywords

CYPROTERONE ACETATE; GONADORELIN DERIVATIVE; TRIPTORELIN;

ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; IDIOPATHIC CENTRAL PRECOCIOUS PUBERTY; MAJOR CLINICAL STUDY; PRECOCIOUS PUBERTY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; ULTRASOUND; UTERUS BLEEDING;

CHILD; CHILD, PRESCHOOL; CYPROTERONE ACETATE; FEMALE; HUMANS; PUBERTY, PRECOCIOUS; RETROSPECTIVE STUDIES; TRIPTORELIN; UTERINE HEMORRHAGE; UTERUS;

EID: 77954064958     PISSN: 16632818     EISSN: 16632826     Source Type: Journal    
DOI: 10.1159/000308172     Document Type: Article

References (18)

1. Partsch CJ, Sippell WG: Treatment of central precocious puberty. Best Pract Res Clin En-docrinol Metab 20 02; 16: 16 5-18 9.
2. Carel JC, Blumberg J, Seymour C, Adams-baum C, Lahlou N: Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty. Eur J Endocrinol 2006; 154:119-124.
3. Conn PM: The molecular basis of gonado-tropin-releasing hormone action. Endocr Rev 1986; 7:3-10.
4. Yeshaya A, Kauschansky A, Orvieto R, Var-sano I, Nussinovitch M, Ben-Rafael Z: Prolonged vaginal bleeding during central precocious puberty therapy with a long-acting gonadotropin-releasing hormone agonist. Acta Obstet Gynecol Scand 1998; 77: 327-329.
5. Dattani MT, Hindmarsh PC: Normal and abnormal puberty; in Brook CGD, Clayton PE, Brown RS (eds): Clinical Pediatric Endocrinology. Malden, Blackwell, 2005, pp 183-210.
6. Mul D, Hughes IA: The use of GnRH agonists in precocious puberty. Eur J Endocrinol 2008; 159(suppl 1):S3-S8.
7. Denmeade SR, Isaacs JT: Androgen deprivation strategies in the treatment of advanced prostate cancer; in Kufe DW, Pollock RE, Weichselbaum RR, Bast RC Jr, Gansler TS, Holland JF, Frei E III (eds): Cancer Medicine. Hamilton, BC Decker, 2003.
8. McEwen BS: Endocrine effects on the brain and their relationship to behavior; in Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD (eds): Basic Neurochemistry. Molecular, Cellular and Medical Aspects. Philadelphia, Lippincott Williams & Wilkins, 1999.
9. Lahlou N, Carel JC, Chaussain JL, Roger M: Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics. J Pediatr Endocrinol Metab 2000; 13(suppl 1):723-737.
10. Garel L, Dubois J, Grignon A, Filiatrault D, Van Vliet G: US of the pediatric female pelvis: a clinical perspective. Radiographics 2001; 21:1393-1407.
11. Greulich WW, Pyle SI: Radiographic Atlas of Skeletal Development of the Ha nd a nd Wrist. Stanford, Stanford University Press, 1959.
12. Comite F, Cutler GB Jr, Rivier J, Vale WW, Loriaux DL, Crowley WF Jr: Short-term treatment of idiopathic precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone. A preliminary report. N Engl J Med 1981; 305:1546-1550.
13. Luder AS, Holland FJ, Costigan DC, Jenner MR, Wielgosz G, Fazekas AT: Intranasal and subcutaneous treatment of central precocious puberty in both sexes with a long-acting analog of luteinizing hormone-releasing hormone. J Clin Endocrinol Metab 1984; 58: 966-972.
14. Chaussain JL, Roger M, Couprie C, Lahlou N, Canlorbe P: Treatment of precocious puberty with a long-acting preparation of D-Trp6-LHRH. Horm Res 1987; 28:155-163.
15. Carel JC, Lahlou N, Jaramillo O, Montauban V, Teinturier C, Colle M, Lucas C, Chaussain JL: Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg). J Clin Endocrinol Metab 2002; 87:4111-4116.
16. Mericq GM, Youlton RR, Willshaw ZM: Effectiveness of leuprolide acetate therapy every three months in central precocious puberty. Rev Med Child 2006; 134:821-826.
17. Liang Y, Wei H, Zhang J, Hou L, Luo X: Efficacy of subcutaneous administration of gonadotropin-releasing hormone agonist on idiopathic central precocious puberty. J Huazhong Univ Sci Technolog Med Sci 2006; 26: 558-561.
18. Mahler C, Verhelst J, Denis L: Clinical phar-macokinetics of the antiandrogens and their efficacy in prostate cancer. Clin Pharmaco-kinet 1998; 34:405-417.